Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Audrey Perrotin

Showing results (31-40 of 42) with videos related to

Pageof 5
Sort By:
Alzheimer'S Research & Therapy|July 27, 2022
Evaluation of tau deposition using <sup>18</sup>F-PI-2620 PET in MCI and early AD subjects-a MissionAD tau sub-studySantiago Bullich, Andre Mueller, Susan De Santi, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|November 16, 2012
Region-specific hierarchy between atrophy, hypometabolism, and β-amyloid (Aβ) load in Alzheimer's disease dementiaRenaud La Joie, Audrey Perrotin, Louisa Barré, et al.
Acta Neuropathologica Communications|March 3, 2019
The elusive tau molecular structures: can we translate the recent breakthroughs into new targets for intervention?Yann Fichou, Youssra K Al-Hilaly, François Devred, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 13, 2019
Tau PET imaging with <sup>18</sup>F-PI-2620 in Patients with Alzheimer Disease and Healthy Controls: A First-in-Humans StudyAndre Mueller, Santiago Bullich, Olivier Barret, et al.
Pharmaceuticals (Basel, Switzerland)|January 8, 2025
Experiences from Clinical Research and Routine Use of Florbetaben Amyloid PET-A Decade of Post-Authorization InsightsAleksandar Jovalekic, Santiago Bullich, Núria Roé-Vellvé, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 13, 2019
Evaluation of Dosimetry, Quantitative Methods, and Test-Retest Variability of <sup>18</sup>F-PI-2620 PET for the Assessment of Tau Deposits in the Human BrainSantiago Bullich, Olivier Barret, Cristian Constantinescu, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|November 7, 2017
Added value of <sup>18</sup>F-florbetaben amyloid PET in the diagnostic workup of most complex patients with dementia in France: A naturalistic studyMathieu Ceccaldi, Thérèse Jonveaux, Antoine Verger, et al.
Alzheimer'S Research & Therapy|March 28, 2021
Early detection of amyloid load using <sup>18</sup>F-florbetaben PETSantiago Bullich, Núria Roé-Vellvé, Marta Marquié, et al.
Brain : a Journal of Neurology|July 1, 2016
Atrophy, hypometabolism and clinical trajectories in patients with amyloid-negative Alzheimer's diseaseGaël Chételat, Rik Ossenkoppele, Victor L Villemagne, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|May 7, 2014
A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's diseaseFrank Jessen, Rebecca E Amariglio, Martin van Boxtel, et al.
Pageof 5

Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
Alzheimer'S Research & Therapy|July 27, 2022
Evaluation of tau deposition using <sup>18</sup>F-PI-2620 PET in MCI and early AD subjects-a MissionAD tau sub-studySantiago Bullich, Andre Mueller, Susan De Santi, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|November 16, 2012
Region-specific hierarchy between atrophy, hypometabolism, and β-amyloid (Aβ) load in Alzheimer's disease dementiaRenaud La Joie, Audrey Perrotin, Louisa Barré, et al.
Acta Neuropathologica Communications|March 3, 2019
The elusive tau molecular structures: can we translate the recent breakthroughs into new targets for intervention?Yann Fichou, Youssra K Al-Hilaly, François Devred, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 13, 2019
Tau PET imaging with <sup>18</sup>F-PI-2620 in Patients with Alzheimer Disease and Healthy Controls: A First-in-Humans StudyAndre Mueller, Santiago Bullich, Olivier Barret, et al.
Pharmaceuticals (Basel, Switzerland)|January 8, 2025
Experiences from Clinical Research and Routine Use of Florbetaben Amyloid PET-A Decade of Post-Authorization InsightsAleksandar Jovalekic, Santiago Bullich, Núria Roé-Vellvé, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 13, 2019
Evaluation of Dosimetry, Quantitative Methods, and Test-Retest Variability of <sup>18</sup>F-PI-2620 PET for the Assessment of Tau Deposits in the Human BrainSantiago Bullich, Olivier Barret, Cristian Constantinescu, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|November 7, 2017
Added value of <sup>18</sup>F-florbetaben amyloid PET in the diagnostic workup of most complex patients with dementia in France: A naturalistic studyMathieu Ceccaldi, Thérèse Jonveaux, Antoine Verger, et al.
Alzheimer'S Research & Therapy|March 28, 2021
Early detection of amyloid load using <sup>18</sup>F-florbetaben PETSantiago Bullich, Núria Roé-Vellvé, Marta Marquié, et al.
Brain : a Journal of Neurology|July 1, 2016
Atrophy, hypometabolism and clinical trajectories in patients with amyloid-negative Alzheimer's diseaseGaël Chételat, Rik Ossenkoppele, Victor L Villemagne, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|May 7, 2014
A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's diseaseFrank Jessen, Rebecca E Amariglio, Martin van Boxtel, et al.
Pageof 5